Quimfa brings global psychiatry and mental health advancements to Paraguay

Paraguayan pharmaceutical company Quimfa recently organized the APA Annual Meeting 2026 – Review Paraguay, an academic event designed to bring the latest global advancements in psychiatry and mental health to the nation's healthcare professionals. The session served as a platform for national specialists to share crucial insights and therapeutic trends discussed at the American Psychiatric Association's (APA) major annual congress held in San Francisco.

The event featured presentations by Paraguayan psychiatrists Aldo Castiglioni, José María Laws, Luis Lezcano, and Osvaldo Melgarejo. These professionals, who attended the international congress as part of the Paraguayan delegation, discussed topics highly relevant to current clinical practice. Key areas covered included the management of patients with multiple medications, the therapeutic potential of psychedelics, emerging treatments for obsessive-compulsive disorder, the influence of artificial intelligence on mental health, the use of GLP-1 agonists, and new approaches to treatment-resistant depression.

Through this initiative, Quimfa reaffirmed its commitment to ongoing medical education and the enhancement of mental health care within Paraguay. The company aims to foster access to cutting-edge scientific information and create professional exchange spaces that support the continuous updating of the national medical community. Quimfa highlighted its pioneering role in facilitating the participation of Paraguayan specialists in one of the world's most significant psychiatric events.

“

This initiative reaffirmed its commitment to continuous medical education and the strengthening of mental health in Paraguay, promoting access to cutting-edge scientific information and generating spaces for professional exchange that contribute to the permanent updating of the national medical body.